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Abstract
Introduction Radiopharmaceuticals may cause adverse events. Knowledge about adverse events from a patient’s perspec-
tive could help healthcare professionals to detect, understand, and manage adverse events more efficiently when using 
radiopharmaceuticals. Researchers need a validated questionnaire that can be used in patients to assess adverse events with 
radiopharmaceuticals.
Objective The aim of this study was to develop, validate the content of, and perform initial testing of a questionnaire assess-
ing patient-reported adverse events of radiopharmaceuticals.
Methods Based on existing literature, six professionals drafted and evaluated a first version of the questionnaire. Further 
content validation was performed using cognitive interviews with six patients undergoing a nuclear medicine examination. 
After adaptations, the questionnaire was developed into a web-based questionnaire. One hundred patients undergoing nuclear 
examination tested this version, and the results were used to assess its acceptability and evaluate reported adverse events.
Results Questions and answer options were revised in the initial questionnaire to improve clarity. In addition, some ques-
tions were removed. The final version consisted of 18 questions. In the test phase, the acceptability of the questionnaire was 
demonstrated (e.g. 79% of the patients who received the questionnaire completed it, and the median time to complete the 
questionnaire was 12 min for patients who reported an adverse event). Of the 100 patients (53% men, median age 64 years), 
12 reported a total of 22 adverse events. One of these adverse events had a high causal association.
Conclusion After validation and testing, the developed questionnaire to study patient-reported adverse events of radiophar-
maceuticals is a suitable and valid instrument which can be used in future research.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 4-019-00895 -2) contains 
supplementary material, which is available to authorized users.
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Key Points 
There are unique aspects inherent in the use of radio- 
pharmaceuticals in nuclear medicine departments that 
need to be included in a questionnaire assessing patient-
reported adverse events of these products.
A questionnaire was developed that can be used for 
research purposes to assess patient-reported adverse 
events of radiopharmaceuticals.
1 Introduction
Radiopharmaceuticals are used in nuclear medicine for 
diagnosis and therapy [1, 2]. While it is known that radi-
opharmaceuticals can cause adverse events, it is assumed 
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that the frequency of adverse events in diagnostic radiop-
harmaceuticals is relatively low compared to events caused 
by other types of drugs [3–8]. This can be explained by 
the low dose of the tracer with a subsequent absence of 
pharmacological effect, and the limited use of the tracer 
in an individual patient—usually only once [3, 4]. How-
ever, underreporting of adverse events—also described for 
other types of drugs—is likely to play a role in this low 
frequency [9–11]. In addition, adverse events of radiop-
harmaceuticals may be left undetected, as follow-up con-
tact seldom occurs between the patient and the nuclear 
medicine department after the examination is completed.
In order to investigate the frequency of adverse events 
and partially overcome the issues of underreporting, infor-
mation provided by the patients themselves can be useful. 
Such information may shed a different light on the fre-
quency of the adverse events, and more detailed informa-
tion aids in assessing the causal relationship between the 
radiopharmaceutical and the reported event. Furthermore, 
information that patients provide may differ from infor-
mation that healthcare professionals provide. Physicians 
generally focus more on serious, often rare adverse events, 
while patients report milder but more frequent adverse 
events such as tiredness [12]. Patients can also provide 
information about the impact of adverse events on their 
quality of life [13, 14]. More knowledge about the fre-
quency of adverse events and the perspective of patients 
could help healthcare professionals to inform patients and 
to better prepare them in managing any adverse event that 
may arise.
Previous research has shown that questionnaires can 
be useful instruments in obtaining information from 
patients about adverse events and about, for instance, the 
time course, severity, and outcome of the adverse events 
[15, 16]. Even though researchers have developed several 
questionnaires in the past [15–17], they were developed 
for other types of drugs and are not suitable for radiop-
harmaceuticals because of aspects that are unique to the 
use of these products in nuclear medicine departments. 
Examples are the specific preparation of the patient before 
the nuclear medicine examination or additional steps dur-
ing the procedure such as physical exercise or the con-
comitant administration of interventional agents, like 
agents that induce stress in the case of the assessment of 
myocardial perfusion. Information about these aspects 
will be essential when assessing reported adverse events. 
Furthermore, the use of radiological contrast agents in 
the case of combined techniques, such as positron emis-
sion tomography/computed tomography (PET/CT), and 
the fact that the nuclear medicine department usually has 
no follow-up contact with the patient after the examina-
tion is completed requires questions to be asked about the 
experience of patients at several specific moments. To our 
knowledge, only one study about radiopharmaceuticals 
assessed adverse events from the perspective of patients. 
In this study, researchers developed and validated a ques-
tionnaire, which 55 patients using Tc-99m medronic acid 
completed. However, this study involved one specific 
radiopharmaceutical and the researchers did not specify 
detailed information about the method of validation [18].
Therefore, we aimed to develop and validate a ques-
tionnaire dedicated to assessing adverse events with radi-
opharmaceuticals from the patient’s perspective, which 
can be used in future research. This paper describes the 
development, content validation, and initial testing of the 
questionnaire.
2  Methods
This study consisted of three phases: (1) the development 
of a questionnaire in the Dutch language, assessing adverse 
events from the perspective of patients undergoing an exami-
nation using radiopharmaceuticals, (2) the validation of its 
content, and (3) initial testing of the questionnaire (Fig. 1). 
We obtained ethical exemption in writing from the Medical 
Ethics Committee of the Isala Hospital, in Zwolle in The 
Netherlands (reference number 16.08138), as this study did 
not require formal approval, according to Dutch law.
2.1  Phase 1: Questionnaire Development
Based on existing literature [3–7, 19, 20], two researchers 
(Q.d.H., N.S.) drafted a first version of the questionnaire 
containing the main questions in the following sections: (1) 
patient characteristics, (2) health status, (3) past nuclear 
medicine examinations and occurrence of adverse events, (4) 
preparation by the patient before a nuclear medicine exami-
nation, (5) administration of the radiopharmaceutical and 
occurrence of adverse events, (6) the period after the nuclear 
medicine examination and occurrence of adverse events, and 
(7) any further comments by the patient.
In section one, we obtained demographic data using 
closed-ended questions (i.e. assessing gender, education—
grouped according to International Standard Classification 
of Education (ISCED) 2011 [21]—and use of over-the-
counter medicines) and open-ended questions (i.e. assessing 
age, weight, and height). Subsequently, in section two, we 
measured the patient’s health status with the EuroQol-5-di-
mensions-3 levels (EQ-5D-3L) questionnaire [22]. The EQ-
5D-3L is a qualified instrument to measure quality of life, 
including a descriptive system and a visual analogue score 
(EQ-VAS) [23]. Permission for its use was obtained. Sec-
tions three, five, and six contained open-ended and closed-
ended questions about adverse events experienced during 
past nuclear medicine examinations, those associated with 
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the administration of the radiopharmaceutical in the cur-
rent nuclear medicine examination, and those experienced 
in the period after the examination, respectively. Section 
four contained closed-ended (both single-answer and mul-
tiple-answer) questions about the preparation by the patient 
before the nuclear medicine examination. In section seven, 
the patient could provide additional remarks about both the 
questionnaire and the nuclear medicine examination.
When patients indicated in the questionnaire that they 
experienced one or more adverse events, we asked addi-
tional closed-ended and open-ended questions, including 
aspects such as experienced symptoms, status of recovery, 
whether patients contacted a healthcare professional, and the 
type of professional (i.e. general practitioner, hospital staff, 
nuclear physician, nurse, pharmacist, and referring physician 
hospital). The additional questions also contained items to 
perform a causality assessment. This concerned the time 
of onset of the adverse event, previous experiences with 
nuclear medicine examinations, administration of interven-
tional agents, or, in the case of combined techniques such 
as PET/CT, the use of contrast agents and other possible 
causes of the adverse event. We based these questions on 
the Naranjo algorithm [24], which is commonly used for 
causality assessment in pharmacovigilance, and the Silber-
stein algorithm [7], which specifically focuses on causality 
assessment of adverse events with radiopharmaceuticals.
A separate section in the questionnaire was meant 
only for the researchers to provide additional information 
obtained from medical records, such as the name of the 
radiopharmaceutical, its dose (in megabecquerel), type of 
examination, renal function, co-medication, and indications 
for use.
2.2  Phase 2: Content Validation
Previously, it has been determined that five experts are the 
minimum requirement for content validation. Moreover, is 
has been suggested that these experts are from all relevant 
disciplines to cover the content domain being assessed [25]. 
We selected six experts with expertise in the field of ques-
tionnaire development (n = 1), pharmacovigilance (n = 2), 
and nuclear medicine (n = 3) to form the expert panel in 
this study. Members of the expert panel independently 
reviewed the first paper-based version of the questionnaire. 
Two researchers (Q.d.H., N.S.) identified issues, which were 
used to draft a second version.
We subjected the second version of the questionnaire to 
cognitive interviewing in order to get insight into the way 
patients understand the questions and how they interpret 
the answer options, highlighting any ambiguities [26]. Six 
patients undergoing a nuclear medicine examination at the 
Isala Hospital in Zwolle participated in this part of the study. 
We selected consecutive patients willing to participate on the 
day of their nuclear medicine examination until we reached 
six participants. They were 18 years old or older and were 
able to read and speak the Dutch language. One researcher 
(Q.d.H.) conducted the interviews and audio-recorded 
them, with approval of the interviewees. In the interview, 
Phase 3: Testing of the questionnairePhase 2: Content validationPhase 1: Questionnaire development




1st version  questionnaire  
2nd version  questionnaire  
Review by expert panel  
Cognitive interviews with 
patients and review
3rd version  questionnaire  Conversion to web-based 
questionnaire  
Review by expert panel
Patients fill in revised web-
based questionnaire
Web-based version of 
questionnaire  
Patient feedback analysed 
and discussed by 
researchers
Fig. 1  Process of development and validation of the questionnaire. Adapted with permission from de Vries et al. (2013) [15]
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the researcher used a set of proactive and reactive so-called 
‘probes’, while the patients were completing the question-
naire. Probes are questions specifically designed to obtain 
detailed information that the interviewee may not otherwise 
share [27]. Examples include ‘How did you come to an 
answer?’ ‘Can you repeat the question in your own words?’ 
and ‘How sure are you of the answer given?’ We transcribed 
the interviews using transcription software (Atlas.ti v7.5.12) 
and analysed the transcripts (Q.d.H.) to identify issues where 
the interviewee had difficulties answering the question. The 
identified issues were coded according to a dedicated system 
containing the following five categories: comprehension/
communication, recall-based, bias/sensitivity, response cat-
egories, and logical/structural problems [28]. Two research-
ers (Q.d.H., NS) discussed the identified issues, which led to 
a third and enhanced version of the questionnaire.
Because the questionnaire is to be sent out to patients 
after a certain time interval after patients have left the 
nuclear medicine department and is to be used in a larger 
group of patients, we converted the paper-based question-
naire into a web-based questionnaire. Furthermore, this ena-
bled the automation of sending the questionnaire after a time 
interval of 7 days after the nuclear medicine examination 
and allowed digital and faster processing of the data. Addi-
tionally, web-based questionnaires have shown some advan-
tages in the past, such as a lower number of unanswered 
questions and more detailed answers to open questions [29]. 
The web-based version of the questionnaire was created 
using an online data manager (De  Researchmanager®) [30]. 
The expert panel tested the web-based questionnaire on user 
friendliness and comprehensiveness. This led to revisions of 
the web-based version.
2.3  Phase 3: Testing of the Questionnaire
We then tested the revised web-based version of the ques-
tionnaire in a larger population of 100 patients to evalu-
ate its acceptability and record adverse events. This is the 
number of patients recommended in literature [31]. Patients 
undergoing nuclear examination at Isala hospital were 
invited to participate in this test phase until we reached 
100 participants who completed the questionnaire. Prior to 
the nuclear examination they received an invitation letter 
with a participation form. Patients were excluded when data 
were missing on the participation form that were required to 
initiate the web-based questionnaire, such as e-mail address 
or signature. We obtained written permission of patients 
willing to participate. Those patients received a link to the 
web-based questionnaire 7 days after their nuclear medicine 
examination. A reminder was sent after another 7 days when 
patients had not completed the questionnaire, but access to 
the questionnaire was limited to 21 days after the nuclear 
medicine examination. These time spans were chosen for 
two reasons. First, we would expect possible adverse events 
to occur within a few days after the nuclear medicine exami-
nation [8]. Second, longer recall periods may introduce bias 
due to patients forgetting information or patients bringing 
up information from other sequential doctor visits or exami-
nations [32–34].
To assess acceptability in patients, we evaluated three 
characteristics: the percentage of patients completing the 
questionnaire, the time in which they completed the ques-
tionnaire, and their ability to answer all questions. We 
recorded the number of patients completing the question-
naire and the time in which they completed it. To assess 
the ability to answer all questions, we added—only during 
the test phase—at the end of each section a question asking 
whether there were any issues with answering the questions 
or with the wording, and, if so, what those issues were.
We evaluated reported adverse events and the time 
course. Reported adverse events were coded according to 
a Preferred Term of the Medical Dictionary for Regula-
tory Activities  (MedDRA®) terminology. MedDRA is the 
international medical terminology developed under the aus-
pices of the International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals 
for Human Use (ICH) [35]. Furthermore, we performed a 
causality assessment on all reported cases using the Naranjo 
[24] and Silberstein [7] algorithms. For the causality assess-
ment, we used data obtained with the questionnaire on the 
time of onset of the adverse event, adverse events during 
previous nuclear medicine examinations, the recovery status 
of the patient, other possible causes of the adverse event 
such as administration of interventional agents, or other 
patient-reported possible causes. To determine if there were 
previous conclusive reports on the reaction or if it was a 
known response pattern, we used data from the literature [8] 
and the summary of product characteristics of the products. 
Two researchers (Q.d.H., N.S.) independently conducted 
the coding and assessed the causality. When results syn-
theses were not in agreement, the results were discussed 
with a third researcher (E.v.P.) to resolve discrepancies. 
After inclusion of the targeted 100 patients, we analysed the 
results descriptively using Excel version 1808 (Microsoft) 
and discussed the analysis to come to a final questionnaire 
(Q.d.H., N.S.).
3  Results
3.1  Phase 1: Questionnaire Development
The first draft of the questionnaire contained 30 main ques-
tions distributed over seven sections and additional ques-
tions about adverse events, which were posed when patients 
indicated they experienced an adverse event.
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3.2  Phase 2: Content Validation
The expert panel provided feedback on the content of the 
first version of the questionnaire. Most of the comments 
related to clarity and wording. Of the 30 questions in the 
first version, we removed six questions, added one question, 
changed four questions, and left 20 questions unchanged. 
Of the six removed questions, five were related to the wait-
ing period for the patient before and after the examination, 
which we deemed irrelevant. The sixth question that was 
removed was about the changes the patients experienced 
during the examination and was found to be repetitive. This 
resulted in a revised, second version of the questionnaire 
(Fig. 1) with 25 main questions.
Thereafter, six patients participated in the cognitive inter-
views. The patients were between 51 years old and 76 years 
old and had varying levels of education. One patient had 
trouble reading the questions due to partial visual impair-
ment. As the interviewer read the questions out loud for 
this patient, the patient was still able to participate. Patients 
mentioned a total of 67 issues, mostly related to the cat-
egories comprehension/communication (52%) and response 
(22%) (Table 1). Of the second version, with 25 main ques-
tions, we left eleven unchanged, removed eight questions 
(because they were difficult to interpret by patients and on 
closer inspection were not considered necessary), revised 
five questions or answer options to improve clarity, com-
bined one question with another, and added two new ques-
tions. The results of the cognitive interviews resulted in a 
third version of the questionnaire (Fig. 1) with a total of 18 
questions. We converted this third version of the question-
naire to a web-based questionnaire.
Next, five of the six members of the expert panel evalu-
ated the web-based version of the questionnaire and made 
66 comments. The most mentioned comments were related 
to spelling, layout, or accompanying texts. One term was 
simplified (i.e. ‘medical professional’ to ‘caregiver’), and 
we changed the wording of two questions. The final ques-
tionnaire (Fig. 1) contained 18 main questions in seven sec-
tions and 12 additional questions (see the Electronic Supple-
mentary Material [ESM], Supplementary Material 1), and 
the expert panel considered it suitable for further testing 
in patients. An English translation of the questions in this 
questionnaire is presented in Table 2. All questions removed 
during the content validation as well as an English transla-
tion can be found in Supplementary Material 2 in the ESM.
3.3  Phase 3: Testing of the Questionnaire
Over the course of 2 months, 650 patients received an invi-
tation letter. Of those, 127 patients provided valid written 
permission to participate in the test phase of the web-based 
questionnaire (Fig. 2). Of these 127 patients receiving the 
questionnaire, 100 completed it (79%). This test popula-
tion consisted of 53% men and 46% women. One patient 
(1%) indicated a different gender or did not want to specify 
gender. The median (interquartile range [IQR]) age was 64 
(56–71) years old (Table 3). Radiopharmaceuticals most 
used were Tc-99m oxidronic acid, Tc-99m tetrofosmin, and 
F-18 fludeoxyglucose. Of the test population, 88% of the 
patients reported no adverse events, and 12% reported one 
Table 1  Number and examples of issues identified during the cognitive interviews with patients per category
A answer by the interviewee, Q question by the interviewer
Category Number (%) Examples of issues mentioned by patients
Comprehension/communication 35 (52.3) Q: “Do you know what contact allergy means?”
A: “Ehmm, that you are afraid to touch people?” (patient 1)
Q: “Do you know what a radioactive agent is?”
A: “I am not sure what it is.” (patient 4)
Recall-based 9 (13.4) Q: “You mentioned your height quite quickly, how certain are you?”
A: “I am not completely sure about my current height, because I think that I shrunk a little over 
the years, so I am not quite sure.” (patient 4)
Bias/sensitivity 3 (4.5) Q: “What do you think by reading this question?”
A: “Oh dear, I have to think about this, and I don’t have that time. So, then I will respond very 
quickly.” (patient 1)
Response categories 15 (22.4) Q: “Can you explain recovering and recovered with sequelae?”
A: “Recovering is the tingling in my hand that decreases, recovered with sequelae is that I still 
have a headache.” (patient 1)
Q: “But doesn’t that mean that you are not recovered at all?”
A: “Oh my, I actually read to fast, when I read it again I will give a different answer.” (patient 1)
Logical/structural 5 (7.5) Q: “Do the examples cover the definition of a medical professional?”
A: “About the examination, uh, no because on Friday I arrived in the hospital and I went here 
unprepared.” (patient 1)
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Table 2  Questions of the questionnaire
*Additional question when 8II answered confirmative
† Additional question when 8II, 12I, 13I, or 16 answered confirmative
ǂ Additional question when 8II or 16 answered confirmative
¶ Additional question when 12I or 13I answered confirmative
# Additional question when 13I answered confirmative
Part Section No. Questions
Main questions Patient characteristics 1 What is your gender?
2 What is your date of birth?
3 What is your weight (kg)?
4 What is your height (cm)?
5 What is your highest level of education?
6 Do you use drugs from the drugstore or self-care products?
Health status 7 Questions about current health status (EQ-5D-3L)
Past nuclear examinations 8 Have you previously undergone a nuclear medical examination?
I. What type of nuclear examination has previously been performed on you?
II. Have you experienced one or more side effects or physical changes that 
you relate to the nuclear examination immediately or within 7 days after this 
examination?
Preparation for nuclear examination 9 What did you think of the patient information you received prior to the examina-
tion?
10 Before the examination did you have to perform one or more of the preparatory 
actions mentioned?
Administration of the radiopharmaceutical 11 What type of nuclear examination has been performed on you?
12 Did you receive a radioactive substance during the examination?
I. Did you notice a possible side effect or physical change shortly after administra-
tion of the radioactive substance?
13 Did you receive an X-ray contrast agent during the study?
I. Did you notice a possible side effect or physical change shortly after administra-
tion of the X-ray contrast agent?
14 In your opinion, did unusual things happen during the investigation?
Time after nuclear examination 15 Did you perform certain actions at home after the examination that were indicated 
from the hospital?
16 Did you experience one or more side effects or physical changes within 7 days 
after the examination that you relate to the nuclear examination?
Other comments 17 Do you have any comments on the complete nuclear examination?
18 Do you have any further remarks?
Additional questions a With what type of nuclear examination did you notice a possible side effect or 
physical change?*
b On what date did the examination take place?*
c Can you briefly describe what happened?†
d How much time was there between administration of the drug and adverse event 
or change?†
e Have you informed your treating doctor/doctor or other healthcare provider?ǂ
f Did you report this adverse event or change to hospital staff?¶
g Was the adverse event or change treated?†
h Have you done something yourself to treat possible side effects or changes?ǂ
i How are the possible side effects or changes at the moment?†
j Did you experience an adverse event before with an X-ray contrast agent?#
k Did the adverse event or change lead to: hospitalisation, a life-threatening situa-
tion, persistent work disability, or congenital defect?*
l In your opinion, are there other circumstances or causes that could have caused or 
worsened this potential side effect?†
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or more adverse events. Patients reporting no adverse event 
completed the questionnaire in a median time of 8 min (IQR 
6–12), and patients who reported an adverse event needed 
12 min (IQR 9–16). With respect to the ability to answer the 
questions, two patients made two comments about the web-
based questionnaire. One patient commented that she did 
not know her exact weight and made an estimation. Another 
patient indicated that she was not sure if a radiopharmaceu-
tical was administered. All other patients stated they had 
no problem in answering the questions and understood all 
words. 
In total, 12 patients reported 22 adverse events. Adverse 
events reported were fatigue (n = 7), nausea (n = 3), abdomi-
nal discomfort (n = 2), chest discomfort (n = 2), feeling hot 
(n = 2), back pain (n = 1), dyspnoea (n = 1), limb discomfort 
(n = 1), pain in extremity (n = 1), paraesthesia (n = 1), and 
sense of oppression (n = 1). Patients reported 15 adverse 
events to have occurred within 1 h after administration 
of the radiopharmaceutical and reported the other seven 
adverse events to have occurred within 7 days after leav-
ing the nuclear department. Patients reported eight adverse 
events with Tc-99m tetrofosmin, two with F-18 fludeoxy-
glucose, and other adverse events with Ra-223 dichloride, 
Tc-99m exametazime–labelled cells, and Tc-99m oxidronic 
acid. We found one adverse event—back pain with Ra-223 
chloride after 7 days—to be probably (Naranjo) and possibly 
(Silberstein) causally related. The other 21 adverse events 
were possibly (Naranjo) or unlikely (Silberstein) to be caus-
ally related. More detail on the adverse events of the radiop-
harmaceutical, and the causality assessment of the adverse 
events can be found in Supplementary Material 3.
4  Discussion
In this study, a questionnaire to assess adverse events of 
radiopharmaceuticals from the perspective of the patient 
was developed, its content was validated, and initial testing 
was conducted. During the test phase, the questionnaire had 
good acceptability in patients. We found that the majority of 
the patients completed the questionnaire, that respondents 
completed the questionnaire in a reasonable time of 8 min 
for those not reporting an adverse event and 12 min for those 
reporting an adverse event, and that a vast majority of the 
patients indicated they had no problem in answering the 
questions and understood all words.
In the content validation part of our study, the expert 
panel and the cognitive interviews with patients identi-
fied several issues. This shows the importance of involving 
patients in the development of a questionnaire, as has been 
noted previously [36]. During the content validation, we 
found that the difference between the radiopharmaceutical, 
Fig. 2  Inclusion process of 
patients in the test phase
Patients provided written permission
(n = 139)
Patients excluded;
No e-mail adres = 6






Patients invited to participate
(n = 650)
Questionnaires not filled in 
(n = 27)
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the interventional drug, and contrast media is not always 
clear to patients. After improving the questionnaire by clari-
fying the questions and putting the questions in a clear order, 
this issue did not occur again. However, this aspect might not 
be completely elucidated, and further research could reveal 
more detail about the reasons why patients do not always 
know the difference between the different pharmaceuticals 
and whether specific information provided to patients could 
improve this understanding.
In the test phase of our study, 12% of the patients reported 
an adverse event of radiopharmaceuticals—with only one 
adverse event assessed to have a higher causal relationship. 
This frequency seems to be higher than the number observed 
in a previous study about radiopharmaceuticals in which one 
out of 55 patients (1.8%) reported three adverse reactions 
[18]. However, that study involved only one specific radi-
opharmaceutical, which was not used in our study. Further 
research in a larger group of patients is needed to establish 
more insight into the frequency and types of adverse effects 
in nuclear medicine.
We performed a causality assessment using two algo-
rithms and found that the categories of the two algorithms 
differ. For example, we found one adverse event to be prob-
ably (Naranjo) and possibly (Silberstein) causally related. 
This difference is inherent to the setup of each of the algo-
rithms. Naranjo’s algorithm uses ten questions with a scor-
ing system assigning causality on the basis of a total score 
in categories ‘definite’, ‘probable’, ‘possible’, or ‘doubt-
ful’. Whereas Silberstein’s algorithm uses categories ‘not 
related’, ‘unlikely’, ‘possible’, or ‘probable’, with specific 
conditions to be met for each category. Also, Naranjo’s algo-
rithm includes questions on aspects such as re-challenge, 
reappearance of the reaction with placebo, drug detection 
in toxic concentrations, and response after dose adjust-
ment which are less relevant for radiopharmaceuticals, and 
which are not included in Silberstein’s algorithm. It might 
be worthwhile to compare both algorithms and examine 
the agreement and correlation of both methods in future 
research. In general, it should be noted that establishing 
a causal relationship between suspected drug and adverse 
event is difficult and that despite the fact that algorithms 
are often used in pharmacovigilance this cannot replace a 
thorough medical examination for an individual case.
Our questionnaire is a useful addition to the already 
existing questionnaires assessing adverse events for other 
types of drugs [15–17] since it focuses on adverse events of 
radiopharmaceuticals and includes aspects that are unique 
to the nuclear medicine examination. The questionnaire not 
only asks the patient about adverse events shortly after the 
examination but also has the possibility to ask about adverse 
events that occur later. The questionnaire includes relevant 
questions to support causality assessment. Although the 
design and validation of this questionnaire was done with 
a Dutch population with its specific cultural characteristics 
and in the Dutch language, we expect that the questionnaire 
is also useful in other populations or languages. However, 
Table 3  Characteristics of patients in the test phase
VAS visual analogue scale
*According to International Standard Classification of Education 
(ISCED) 2011 [21]
† Based on the Dutch algorithm for the EuroQol (EQ-5D) scores; util-
ity scores range from 0 (death) to 1 (full health)
ǂ Two patients indicated 0 and might not have been able to move the 
scale correctly
Characteristics Patients (n = 100)
Gender
 Women, n 46 (46%)
 Men, n 53 (53%)
 Different/does not want to say, n 1 (1%)
Age (years), median (25th–75th percentile) 64 (56–71)
Weight (kg), median (25th–75th percentile) 80 (68–91)
Height (cm), median (25th–75th percentile) 176 (168–187)
Education*
 Early childhood education, n 2 (2%)
 Primary education, n 5 (5%)
 Lower secondary education, n 18 (18%)
 Upper secondary education, n 9 (9%)
 Post-secondary non-tertiary education, n 29 (29%)
 Bachelor’s degree or equivalent level, n 31 (31%)
 Master’s degree or equivalent level, n 6 (6%)
Patients using over-the-counter medicines, n 66 (66%)






 EQ-5D index value, median (25th–75th percen-
tile)
0.81 (0.73–0.92)†
 EQ-VAS, median (25th–75th percentile) 65 (50–80)ǂ
First injection with radiopharmaceutical, n 64 (64%)
Radiopharmaceutical
 Tc-99m oxidronic acid 30 (30%)
 Tc-99m tetrofosmin 25 (25%)
 F-18 fludeoxyglucose 24 (24%)
 F-18 fluorocholine 4 (4%)
 Tc-99m nanocolloid 4 (4%)
 I-123 sodium iodine (capsule) 2 (2%)
 Tc-99m pertechnetate 2 (2%)
 Other 9 (9%)
Patients reporting at least one adverse event 12 (12%)
Time to complete questionnaire (min), median (25th–75th percentile)
 For patients reporting no adverse events 8 (6–12)
 For patients reporting adverse events 12 (9–16)
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validation of a translated version is required. Also, valida-
tion of the Dutch version has not ended, as it is a continuous 
process with, for instance, the possibility of changes in the 
interpretation of questions over time [37].
The strength of our study is the systematic development 
and validation of the questionnaire and the testing in a large 
number of patients. However, we must acknowledge sev-
eral limitations of our study. One limitation is that we inter-
viewed a limited number of six patients during the content 
validation. Although research indicates that a small group 
will reveal most critical problems [38], we cannot dismiss 
the possibility that a larger number of patients might have 
revealed additional issues. Another limitation is that data 
obtained in the test phase might be prone to bias [39]. Of the 
patients initially invited, 15% completed the questionnaire, 
and we did not ask patients the reasons for not participat-
ing. Furthermore, the education of the population in the test 
phase seems somewhat higher (37% having a bachelor’s 
degree, master’s degree, or equivalent level) in comparison 
with the general population (30% having a bachelor’s degree, 
master’s degree, or equivalent level [40]). Because of the 
choice to use a web-based questionnaire, some patients may 
not have been able to participate. On the other hand, internet 
access is rapidly increasing, which will enable more and 
more patients to participate in web-based questionnaires 
[41].
5  Conclusion
We developed a questionnaire to be used for studies to assess 
adverse events of radiopharmaceuticals from the perspec-
tive of the patient. After extensive validation and testing by 
experts and patients, this questionnaire proved to be suit-
able and valid. Researchers could use the questionnaire in 
further studies to learn more about adverse events of radi-
opharmaceuticals in a larger population, and this could 
be helpful for identifying potential adverse events of new 
radiopharmaceuticals.
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